Keros Therapeutics (KROS) Capital Expenditures (2019 - 2026)
Keros Therapeutics' Capital Expenditures came in at $134,000 for Q4 2025, down 53.6% from $289,000 a year earlier but up 1.5% from the prior quarter.
Powered by 
Analysis
Keros Therapeutics (KROS) Capital Expenditures (2019 - 2026) Analysis & Trends
For FY2025, Keros Therapeutics' Capital Expenditures was $1.55 million, down 19.7% from FY2024.
- Capital Expenditures carries a five-year compound annual growth rate of 39.5% (FY2020 to FY2025).
- Going back by year, Capital Expenditures was $1.93 million in FY2024 (-21.6%), $2.46 million in FY2023 (+98.5%), $1.24 million in FY2022 (+21.2%) and $1.02 million in FY2021 (+248.3%).
- The five-year range for quarterly Capital Expenditures is $132,000 (Q3 2025) to $1.06 million (Q1 2023).
- Year-over-year, Capital Expenditures increased in 1 of the last eight quarters, with an average decline of 14.4%.
- The fastest year-over-year change in Capital Expenditures over five years came in Q1 2023 (growth of 622.4%), and the weakest in Q3 2025 (a decline of 65.8%).
- Business Quant data shows KROS's Capital Expenditures at $132,000 (Q3 2025), $720,000 (Q2 2025) and $565,000 (Q1 2025) in the three quarters before Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn | 3.18 Bn |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn | 1.36 Bn |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn | 301.00 Mn |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn | 1.04 Bn |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn | -3.30 Bn |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn | 587.00 Mn |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn | 237.00 Mn |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn | 573.00 Mn |
| 10 | Keros Therapeutics | 185.02 Mn | -900.96 Mn | - | 59,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | 59,000.00 |
| Jun 30, 2026 | 155,000.00 |
| Mar 31, 2026 | 73,000.00 |
| Dec 31, 2025 | 134,000.00 |
| Sep 30, 2025 | 132,000.00 |
| Jun 30, 2025 | 720,000.00 |
| Mar 31, 2025 | 565,000.00 |
| Dec 31, 2024 | 289,000.00 |
| Sep 30, 2024 | 386,000.00 |
| Jun 30, 2024 | 310,000.00 |
| Mar 31, 2024 | 946,000.00 |
| Dec 31, 2023 | 541,000.00 |
| Sep 30, 2023 | 550,000.00 |
| Jun 30, 2023 | 311,000.00 |
| Mar 31, 2023 | 1.06 Mn |
| Dec 31, 2022 | 351,000.00 |
| Sep 30, 2022 | 176,000.00 |
| Jun 30, 2022 | 567,000.00 |
| Mar 31, 2022 | 147,000.00 |
| Dec 31, 2021 | 159,000.00 |
API Access
Keros Therapeutics Capital Expenditures API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=capital-expenditures&ticker=KROS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "capital-expenditures", "ticker": "KROS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=capital-expenditures&ticker=KROS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();